Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Recruiting now · Phase 2

Conditions studied: Parkinson Disease

In brief

Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.

Key facts

Study ID

NCT07001150

Run by

Tanta University

People needed

50

Starts

2025-05-10

Expected to finish

2026-05-30

Last updated by the study team

2025-09-10

Who can join

Age: 45 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 45 and 65 years old
• Both sexes
• Patients with Parkinson's disease on dopamine replacement therapy
• Modified Hoehn and Yahr stage, MHY 1-4 (29)

You may not qualify if…

• Subjects < 18 years of age
• Pregnant or breastfeeding women
• Suspected hypersensitivity to silymarin or multivitamins
• Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy)
• Subjects with morbid obesity, i.e., a Body Mass Index (BMI) > 40
• Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)>7%
• Current use of Silymarin or recent use within the past two weeks.
• Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.

Where it is running

• Tanta Hospital for Mental Health — Tanta, Tanta, Qism 2, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.